Related Experiment Videos
Haloperidol decanoate: a depot antipsychotic.
C A Hemstrom1, R L Evans, F G Lobeck
1College of Pharmacy, Idaho State University, Pocatello 83209.
Drug Intelligence & Clinical Pharmacy
|April 1, 1988
Summary
Haloperidol decanoate (HD) is an effective depot antipsychotic for selected schizophrenia patients, improving compliance and outcomes. It is recommended for chronic, relapsing cases that have responded to oral haloperidol.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Psychiatry
Background:
- Depot antipsychotic formulations offer potential advantages in medication adherence.
- Haloperidol decanoate (HD) represents a long-acting injectable option for antipsychotic therapy.
- Comparing HD with oral and other injectable antipsychotics is crucial for treatment selection.
Purpose of the Study:
- To review the role and optimal use of haloperidol decanoate (HD) as a depot antipsychotic.
- To evaluate the efficacy, safety, and pharmacokinetics of HD in comparison to other treatments.
- To provide clinical guidelines for the effective management of patients receiving HD.
Main Methods:
- Review of existing clinical research on haloperidol decanoate in human subjects.
- Analysis of chemical properties, indications, contraindications, and pharmacokinetics of HD.
- Evaluation of efficacy, adverse effects, and dosing strategies based on available data.
Main Results:
- Haloperidol decanoate (HD) is confirmed as an effective antipsychotic dosage form.
- HD demonstrates potential to improve patient compliance and treatment outcomes.
- HD is most suitable for chronic, relapsing schizophrenic patients previously responsive to oral haloperidol.
Conclusions:
- Haloperidol decanoate (HD) is a valuable tool for specific patient populations with schizophrenia.
- Clinicians must consider pharmacokinetics, risks, and costs for optimal HD utilization.
- Guidelines are presented to assist healthcare providers in the effective prescription and management of HD.